Applied DNA Sciences received formal notification from Nasdaq on June 27, 2024, confirming its compliance with Listing Rule 5550(b)(1), which requires maintaining stockholders' equity of at least $2.5 million on The Nasdaq Capital Market. This confirmation was based on information provided in the company's Form 8-K dated June 18, 2024.The company must continue to demonstrate compliance with the Stockholders' Equity Requirement in its next periodic report to maintain its listing status. If compliance is not evidenced, the company may face potential delisting, though it would have the right to appeal such determination to a Hearings Panel.

Applied DNA Sciences received formal notification from Nasdaq on June 27, 2024, confirming its compliance with Listing Rule 5550(b)(1), which requires maintaining stockholders' equity of at least $2.5 million on The Nasdaq Capital Market. This confirmation was based on information provided in the company's Form 8-K dated June 18, 2024.The company must continue to demonstrate compliance with the Stockholders' Equity Requirement in its next periodic report to maintain its listing status. If compliance is not evidenced, the company may face potential delisting, though it would have the right to appeal such determination to a Hearings Panel.